Isopropylnorsynephrine (Deoxy)
Isopropylnorsynephrine (isopropyloctopamine, 'Deoxy') is a synthetic beta-adrenergic sympathomimetic marketed in topical and oral fat-loss products for targeted lipolysis. It has essentially no human safety data and carries the cardiovascular cautions of potent beta-agonists.
01 Overview
Isopropylnorsynephrine is a synthetic analog of octopamine/synephrine designed as a beta-adrenergic agonist. It appears in 'stubborn fat' serums and some oral fat-burners, promoted for localised lipolysis when applied to skin.
Human research is absent, and its beta-agonist activity raises concerns about heart rate and blood pressure, especially in oral use or when stacked with other stimulants.
02 Mechanism
Beta-adrenergic receptor agonist that stimulates lipolysis in fat cells and can increase heart rate and cardiac output.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Oral (uncommon) | 25–50 mg | Oral | Rare oral use; safety unknown. |
| Topical | 100–250 mg/day | Transdermal | Applied topically in 'stubborn fat' serums; no validated dose. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Localised lipolysisBeta-agonism may increase fat breakdown at application site. | Unclear | Preclinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| TachycardiaBeta-agonist activity can raise heart rate, especially with oral use or stacking. | Moderate | Unquantified | Preclinical | |
| Blood pressure changesAdrenergic activity can alter blood pressure unpredictably. | Moderate | Unquantified | Preclinical |